Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Adakveo Fails A Phase III Study
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
